A Therapy for Most with Cystic Fibrosis
- PMID: 31978337
- DOI: 10.1016/j.cell.2019.12.032
A Therapy for Most with Cystic Fibrosis
Abstract
TRIKAFTA is the third drug approved by the FDA that rescues defects caused by the major mutation F508del. It is superior to its predecessors that were approved for patients who are homozygous for F508del because TRIKAFTA is also effective in CF patients who harbor only one copy of this mutation.
Copyright © 2019. Published by Elsevier Inc.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
